Oliver Fetzer Net Worth

The estimated Net Worth of Oliver Fetzer is at least 871 千$ dollars as of 13 June 2019. Oliver Fetzer owns over 1,525 units of Arena Pharmaceuticals Inc stock worth over 417,858$ and over the last 8 years he sold ARNA stock worth over 85,232$. In addition, he makes 367,633$ as Independent Director at Arena Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Oliver Fetzer ARNA stock SEC Form 4 insiders trading

Oliver has made over 1 trades of the Arena Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,525 units of ARNA stock worth 85,232$ on 13 June 2019.

The largest trade he's ever made was selling 1,525 units of Arena Pharmaceuticals Inc stock on 13 June 2019 worth over 85,232$. On average, Oliver trades about 218 units every 0 days since 2017. As of 13 June 2019 he still owns at least 4,179 units of Arena Pharmaceuticals Inc stock.

You can see the complete history of Oliver Fetzer stock trades at the bottom of the page.

Oliver Fetzer biography

Dr. Oliver S. Fetzer Ph.D. serves as Independent Director of the Company. Dr. Fetzer has served on our Board of Directors since February 2017. He has served as the Chief Executive Officer of Synthetic Genomics, Inc., a private synthetic biology company commercializing genomic technologies, since November 2014. Prior to Synthetic Genomics, Dr. Fetzer was President and Chief Executive Officer of Cerulean Pharma Inc., a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics, from April 2009 to October 2014. Prior to Cerulean Pharma, Dr. Fetzer served in a variety of positions at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Research & Development, Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Business Development. Dr. Fetzer began his career in 1993 in various positions of increasing responsibility at the Boston Consulting Group (BCG), a global leading management consulting firm, including Consultant, Project Leader, Principal, Partner and Managing Director. Dr. Fetzer served on the boards of Auxilium Pharmaceuticals, Inc. from 2005 to 2015 and of Cerulean Pharma, Inc. from 2009 to 2014, and has served on the board of Tecan Group AG, a publicly traded provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics, since 2011. Dr. Fetzer received a B.S. in Biochemistry from the College of Charleston, a Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an M.B.A. from Carnegie Mellon University.

What is the salary of Oliver Fetzer?

As the Independent Director of Arena Pharmaceuticals Inc, the total compensation of Oliver Fetzer at Arena Pharmaceuticals Inc is 367,633$. There are 14 executives at Arena Pharmaceuticals Inc getting paid more, with Amit Munshi having the highest compensation of 8,931,400$.

How old is Oliver Fetzer?

Oliver Fetzer is 56, he's been the Independent Director of Arena Pharmaceuticals Inc since 2017. There are 4 older and 9 younger executives at Arena Pharmaceuticals Inc. The oldest executive at Arena Pharmaceuticals Inc is Garry Neil, 67, who is the Independent Director.

What's Oliver Fetzer's mailing address?

Oliver's mailing address filed with the SEC is C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO, CA, 92121.

Insiders trading at Arena Pharmaceuticals Inc

Over the last 21 years, insiders at Arena Pharmaceuticals Inc have traded over 9,243,184$ worth of Arena Pharmaceuticals Inc stock and bought 78,040 units worth 252,505$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Manmeet Singh Soni、Garry Arthur Neil. On average, Arena Pharmaceuticals Inc executives and independent directors trade stock every 39 days with the average trade being worth of 3,133,387$. The most recent stock trade was executed by Amit Munshi on 16 August 2021, trading 1,000 units of ARNA stock currently worth 48,190$.

What does Arena Pharmaceuticals Inc do?

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas

Complete history of Oliver Fetzer stock trades at Arena Pharmaceuticals Inc

Arena Pharmaceuticals Inc executives and stock owners

Arena Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Amit Munshi,
  Director, President and Chief Executive Officer
• Vincent Aurentz,
  Executive Vice President and Chief Business Officer
• Robert Lisicki,
  Executive Vice President and Chief Commercial Officer
• Amit D. Munshi M.B.A.,
  Pres, CEO & Director
• Vincent E. Aurentz,
  Exec. VP & Chief Bus. Officer
• Dr. Christopher H. Cabell FACC, M.D., MHS,
  Advisor
• Laurie D. Stelzer,
  Exec. VP & CFO
• Joan Schmidt,
  Exec. VP, Gen. Counsel & Sec.
• Tina Nova,
  Independent Chairman of the Board
• Jennifer Jarrett,
  Independent Director
• Randall Woods,
  Independent Director
• Jayson Dallas,
  Independent Director
• Manmeet Soni,
  Independent Director
• Kieran Gallahue,
  Independent Director
• Oliver Fetzer,
  Independent Director
• Garry Neil,
  Independent Director
• Katharine Knobil,
  Director
• Joan Schmidt,
  Executive Vice President, General Counsel, Secretary
• Laurie Stelzer,
  Chief Financial Officer, Executive Vice President
• Patrick Malloy,
  VP of Investor Relations & Corp. Communications
• Megan E. Knight,
  Director of Investor Relations
• Dr. Lamine Mbow Ph.D.,
  Sr. VP & Chief Scientific Officer
• Dr. Douglas A. Bakan Ph.D.,
  Exec. VP of Technical Operations
• Harry F Jr Hixson,
  Director
• Maurice James Mezzino,
  SVP, Corporate Development
• Phillip M Schneider,
  Director
• Preston Klassen,
  EVP and CMO
• Steven W Spector,
  EVP, General Counsel & Sec
• Scott H Bice,
  Director
• Kevin Robert Lind,
  Executive VP and CFO
• Christine Anna White,
  Director
• Donald D Belcher,
  Director
• Nawal Ouzren,
  Director
• Frederick Frank,
  
• Mark N Lampert,
  Director
• Robert Hoffman,
  SVP, Finance and CFO
• Partners L P/Ilbiotechnolog...,
  
• James Laforce,
  Director
• Jennifer Kathleen Bielasz,
  VP, Accounting & Controller
• K A Ajit Simh,
  VP, Quality Systems
• Jack Lief,
  Chairman, President and CEO
• Craig Michael Audet,
  SVP, Opn & Head Glob Reg Afrs
• Duke K Bristow,
  Director
• Robert L Toms,
  Director
• Paul W Maffuid,
  VP, Pharmaceutical Development
• Joyce H Williams,
  VP, Drug Development
• Partners L P/Ilbvf Inc/Ilbi...,
  
• Nigel R A Beeley,
  VP, Chief Chemical Officer
• Joseph F Mooney,
  Chief Financial Officer
• Derek T Chalmers,
  Vice President, Research
• Louis J Scotti,
  VP, Marketing and Bus Dev
• Dominic P Behan,
  EVP & Chief Scientific Officer
• James Edeerfield Capital Lp...,
  
• Louis J Jr Lavigne,
  Director
• William R Jr Shanahan,
  SVP & Chief Medical Officer
• Christopher Cabell,
  EVP, Head of R&D, and CMO
• Steven J Schoch,
  Director
• Douglas J. Manion,
  EVP Research & Development